



The Synthetic Gene Therapy Company

Eukarÿs publishes the construction process of C3P3-G1, the prototype of the C3P3 artificial expression system

Evry, February 6, 2019,

In the February 6 issue of Nucleic Acid Research, Eukarÿs publishes the construction process for the first generation of its C3P3 artificial expression system. This one, denominated C3P3-G1, was developed by synthetic biology according to a complex and methodical strategy. Although the C3P3-G1 is a prototype whose performance is far below that of the 3rd generation C3P3 system currently in use, it remains important because it is the technological foundation on which the system was built.

Nucleic Acids Research, gkz069, <https://doi.org/10.1093/nar/gkz069>

Jais PH, Decroly E, Jacquet E, Le Boulch M, Jais A, Jean-Jean O, et al. C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system. Nucleic acids research. 2019, 1-18.

About Eukarÿs

Eukarÿs is a French biotech company of the Ile-de-France Genopole biocluster. Using its C3P3 expression system, Eukarÿs is developing a new approach to non-viral synthetic gene therapy that is efficient, safe, well tolerated, inexpensive and usable for the treatment of most monogenic or multifactorial human diseases. The C3P3 system is also used for the development of powerful tools for the bioproduction of proteins and recombinant viruses.

Contact : Eukarÿs SAS | Genopole Campus 3 | 4 rue Pierre Fontaine | 91058 Evry Cedex, France | contact@eukarys.com | www.eukarys.com